The National Pharmaceutical Pricing Authority (“NPPA”) through orders dated 3rd November, 2020 has fixed the ceiling price for TD Vaccine, Tacrolimus, Praziquantel and Sodium nitrite for specified dosage form & strength and unit.
Additional Guidelines :
(a) All manufacturers of Scheduled formulation, selling the branded or generic or both the versions of Scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, must revise the prices of all such formulations downward not exceeding the ceiling price specified plus goods and services tax as applicable.
(b) All the existing manufacturers of above mentioned Scheduled formulations having MRP lower than the ceiling price specified plus goods and services tax as applicable, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned.
(d) The ceiling price for a pack of the Scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(e) Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of Scheduled formulation with dosage or strength or both as specified launches a new drug such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(g) The manufacturers of above said Scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of Scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said Scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of Scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling price of such formulation as specified in the notifications, the price order(s) fixing ceiling or retail price, issued prior to the above said date of notification, stand(s) superseded.
Source : National Pharmaceutical Pricing Authority
